What question did this study set out to answer?

To compare clinical features, survival, relapse, and mortality between Down syndrome-related myeloid leukemia and standard acute myeloid leukemia occurring in children with Down syndrome.

September 17, 2026Annals of HematologyOpen Access

Outcomes of down syndrome-related myeloid leukemia in Turkiye: a multicenter retrospective observational cohort study by the Turkish Pediatric Hematology Association

View Full Paper

Ask AI

Bookmark

Authors

YKYeter Düzenli Kar HÖHale Ören MEMelike Sezgin Evim

Discussion

Member takes

Overview

Retrospective cohort study reveals superior survival in Down syndrome myeloid leukemia versus standard acute myeloid leukemia, indicating the need for subtype-specific treatment intensity.

Key Points

To compare clinical features, survival, relapse, and mortality between Down syndrome-related myeloid leukemia and standard acute myeloid leukemia occurring in children with Down syndrome.
Multicenter retrospective cohort study across Turkish Pediatric Hematology Association centers including newly diagnosed pediatric patients aged 6 months to 18 years (N = 53).
Patients were classified according to WHO guidelines and BFM-AML protocols into Down syndrome-related myeloid leukemia (DS-ML, n = 38) or standard acute myeloid leukemia (standard AML-DS, n = 15).
Patients with DS-ML presented at a significantly younger mean age than those with standard AML-DS (23 ± 9 months vs. 48 ± 51 months, p = 0.033).
Five-year overall survival was significantly higher in the DS-ML group compared to the standard AML-DS group (84.1% ± 6.0% vs. 53.3% ± 12.9%, p = 0.039).
Five-year event-free survival was significantly higher in the DS-ML group compared to the standard AML-DS group (81.3% ± 6.4% vs. 45.7% ± 13.1%, p = 0.025).

Cite This Study

Kar et al. (2026) studied this question.

synapsesocial.com/papers/6aabb6f95f706d05830e5c73 https://doi.org/10.1007/s00277-026-07245-0

View Full Paper

Ask AI

Bookmark

September 17, 2026Annals of HematologyOpen Access

Outcomes of down syndrome-related myeloid leukemia in Turkiye: a multicenter retrospective observational cohort study by the Turkish Pediatric Hematology Association

View Full Paper

Ask AI

Bookmark

Authors

YKYeter Düzenli Kar HÖHale Ören MEMelike Sezgin Evim

Discussion

Member takes

Overview

Retrospective cohort study reveals superior survival in Down syndrome myeloid leukemia versus standard acute myeloid leukemia, indicating the need for subtype-specific treatment intensity.

Key Points

To compare clinical features, survival, relapse, and mortality between Down syndrome-related myeloid leukemia and standard acute myeloid leukemia occurring in children with Down syndrome.
Multicenter retrospective cohort study across Turkish Pediatric Hematology Association centers including newly diagnosed pediatric patients aged 6 months to 18 years (N = 53).
Patients were classified according to WHO guidelines and BFM-AML protocols into Down syndrome-related myeloid leukemia (DS-ML, n = 38) or standard acute myeloid leukemia (standard AML-DS, n = 15).
Patients with DS-ML presented at a significantly younger mean age than those with standard AML-DS (23 ± 9 months vs. 48 ± 51 months, p = 0.033).
Five-year overall survival was significantly higher in the DS-ML group compared to the standard AML-DS group (84.1% ± 6.0% vs. 53.3% ± 12.9%, p = 0.039).
Five-year event-free survival was significantly higher in the DS-ML group compared to the standard AML-DS group (81.3% ± 6.4% vs. 45.7% ± 13.1%, p = 0.025).

Cite This Study

Kar et al. (2026) studied this question.

synapsesocial.com/papers/6aabb6f95f706d05830e5c73 https://doi.org/10.1007/s00277-026-07245-0

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark